Australian Medical Angels raising $40m fund, hires ex-Startmate CEO as venture partner
## The Move Australian Medical Angels, a Sydney angel syndicate run by doctors, is raising a $40 million fund and hired Michael Batko as venture partner. Batko ran Startmate for eight years, backed 220 companies, and built a portfolio worth $3.5 billion. He stepped down in early 2026 and joined Medical Angels in March to handle the raise, investor relations, and operations. The fund hit $4 million in commitments in 10 weeks. It is structured as an Early Stage Venture Capital Limited Partnership (ESVCLP), targeting digital health, MedTech, healthcare SaaS, and low-risk medical devices. ## What It Means for Sales More funded health tech startups means more med device and health tech sales roles in ANZ. Medical Angels has backed 30 companies since 2017, all still operating, including Smileyscope (VR-based pain management) and Coviu (telehealth platform running 300,000 monthly consultations). If you are tracking med device sales opportunities, watch Medical Angels portfolio companies. They focus on rural health and healthcare equity, which means selling into underserved markets, not just metro hospitals. ## The Comp Context VC-backed med device startups typically hire sales reps during or after seed rounds. Entry-level med device sales reps in Australia earn $60k to $80k base, with OTE around $100k to $120k. Senior sales directors at established med device companies pull $180k to $250k OTE. Early-stage health tech companies often sit below these benchmarks but offer equity upside. Operating partners at VC firms, Batko's new role, typically earn $150k to $300k base depending on fund size and scope. Medical Angels is smaller than funds like Medtronic Ventures or SV Health Investors, but Batko's part-time arrangement and startup equity (he co-founded Hourglass AI) suggests comp is structured around carried interest and portfolio performance. ## Why This Matters Australian Medical Angels is doctor-led, which means clinical validation before investment. That matters for sales teams pitching to hospitals: portfolio companies have built-in clinical credibility. The $40 million fund is small compared to US players like Versant Ventures, but in ANZ early-stage health tech, it is a meaningful capital source. Batko's network from Startmate adds distribution. If you are hiring or job hunting in ANZ health tech sales, track this fund's portfolio announcements.